# IPDA for High-Priority HIV-1 Subtypes to Enable Global Eradication Trials

> **NIH NIH N43** · ACCELEVIR DIAGNOSTICS, LLC · 2020 · $299,975

## Abstract

Sequence-based Assays to Quantify the Replication-Competent HIV Reservoir: Despite effective antiretroviral therapy (ART), HIV-1 persists in all infected individuals as proviral DNA within long-lived memory CD4+ T cells. This replication-competent HIV reservoir constitutes the primary barrier for curing HIV infection. The overall goal of this program is to develop and commercialize sequence-based HIV reservoir assays for clinical HIV cure interventions. Specifically, the assay should be designed as an analytical tool to monitor the size of the replication-competent HIV reservoir in clinical research and if successful, in prospective clinical trials.

## Key facts

- **NIH application ID:** 10215310
- **Project number:** 75N93020C00015-0-9999-1
- **Recipient organization:** ACCELEVIR DIAGNOSTICS, LLC
- **Principal Investigator:** GREGORY LAIRD
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $299,975
- **Award type:** —
- **Project period:** 2020-06-01 → 2021-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10215310

## Citation

> US National Institutes of Health, RePORTER application 10215310, IPDA for High-Priority HIV-1 Subtypes to Enable Global Eradication Trials (75N93020C00015-0-9999-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10215310. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*